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AbstrAct
Type 2 diabetes mellitus (T2DM), cardiovascular disease (CvD) and the cardiovascular effect of 
antidiabetic drugs are today critical medical issues, with the prevalence of T2DM in particular 
showing a steep increase worldwide, mainly due to unhealthy lifestyle habits. T2DM in associa-
tion with obesity and other cardiovascular risk factors, results in the development of CvD, the 
leading cause of morbidity and mortality in patients with T2DM. Thus, treatment of T2DM is 
an individualized and complex challenge in which targeting cardiovascular risk factors is an 
important component in the decision making. given the cardiovascular adverse events associ-
ated with rosiglitazone, both the food and Drug Administration and the european Medicines 
Agency currently require the demonstration of cardiovascular safety of new antidiabetic drugs. 
Consequently, clinical trials to guarantee their cardiovascular safety are now obligatory. This 
review aims to summarize the available evidence on the cardiovascular effects and safety of 
the major drugs used in T2DM treatment and also to provide an overview of upcoming and 
ongoing clinical trials in this field. Our belief is that this review will be of substantial assistance 
to all medical doctors who are treating diabetic patients, namely primary care physicians, in-
ternal medicine doctors, endocrinologists, diabetologists and less well experienced personnel 
such as young doctors in training.
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INTRODUCTION
Cardiovascular disease (CVD) remains the leading 
cause of morbidity and mortality in patients with type 
2 diabetes mellitus (T2DM).1 Given that drugs used 
in the treatment of T2DM may have either beneficial 
or harmful cardiovascular (CV) effects, it is vital to 
ensure that these drugs have no deleterious CV effects 
and may actually improve CV outcomes. On this ac-
count, the Food and Drug Administration (FDA) in 
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2008 and the European Medicines Agency (EMA) 
in 2010 recommended that new compounds being 
developed for T2DM should undergo clinical trials 
to guarantee CV safety.2,3 However, the CV effects of 
most antidiabetic drugs are not as yet elucidated4 and 
there is little evidence from randomized trials regarding 
how best to treat T2DM in the CVD affected popula-
tion. The American Diabetes Association (ADA) and 
the European Association for the Study of Diabetes 
(EASD) have reported a consensus algorithm for 
managing T2DM5 in which metformin is the initial 
pharmacologic agent of choice combined with other 
drugs in double or triple therapy. Our review aims 
to summarize the CV issues related to the core drugs 
used in T2DM (Table 1) and to provide an overview 
of the status of the ongoing and upcoming clinical 
trials in this field. 
INsULIN 
Insulin is the primary treatment for type 1 dia-
betic patients and for type 2 diabetic patients whose 
hyperglycemia does not respond to other antidiabetic 
drugs.6 The initial step of insulin action occurs after 
its binding to the insulin receptor, which leads to the 
activation of two major pathways of considerable 
complexity: the mitogenic pathway, mediating the 
growth effects of insulin through the mitogen-activated 
protein kinase (MAPK), and the metabolic pathway 
which regulates nutrient metabolism by activation of 
phosphatidylinositol 3-kinase (PI3K). Different types 
of insulin are now available and categorized by their 
source and time of action.7 Some authors believe that 
individuals with insulin resistance, mainly affecting 
the PI3K pathway, need greater amounts of insulin 
to achieve a similar glycemic control, whilst MAPK 
pathway overstimulation leads to an acceleration of 
the atherosclerotic process within the vessel wall.8 
Older in vivo animal studies provided evidence of the 
atherogenic potential of insulin.9 Conversely, several 
studies have pointed to a possible anti-atherosclerotic 
effect of insulin mediated by nitric oxide release10 
as well as inhibition of pro-apoptotic signals11 and 
of platelet aggregation.12 However, at present there 
are no unequivocal clinical data about these effects, 
which may also depend on the physiological or else 
experimental circumstances. The main side effects 
insulin are hypoglycemia and weight gain, while se-
vere hypoglycemia can increase the risk of dementia, 
CV events and death.13 
CARDIOvAsCULAR sAfeTy Of INsULIN: 
evIDeNCe fROM sTUDIes
Several studies have reported an increase in CV 
risk and higher mortality,14 whereas others have dem-
onstrated a reduction in CV events, apart of their raise 
in the incidence of hypoglycemia.15 An observational 
study of patients on insulin plus metformin reported 
a higher risk of a composite effect of nonfatal CV 
and all-cause mortality among insulin therapy users 
compared to those administered sulfonylureas (SU) 
as an add-on therapy.16 However, significant bias 
might be present considering that patients with more 
severe disease are more likely to be treated with 
insulin. A recently published post hoc analysis of 
the action to control cardiovascular risk in diabetes 
(ACCORD) trial suggests that insulin dose did not 
play a role in the greater CV mortality in patients 
randomized to intensive glycemic control.17 In the 
sulfonylurea/insulin arm of the United Kingdom 
Prospective Diabetes Study (UKPDS), there was 
no association between the use of insulin and CVD 
incidents,18 even after 10 years of follow-up.19 The 
Outcome Reduction with Initial Glargine Intervention 
(ORIGIN) trial with the long-acting insulin glargine 
involved more than 12,000 patients with new-onset or 
early T2DM, impaired glucose tolerance or impaired 
fasting glucose, with a prior CV event or at high risk 
for CVD, who were randomized either to glargine 
or to standard care. The results demonstrated no as-
sociation with macrovascular events in both groups. 
However, there was a positive link to both weight 
gain and hypoglycemia.20 The ORIGIN trial and the 
recently published legacy effects (ORIGINALE) 
study followed up these patients for more 2.5 years 
and confirmed that insulin glargine had neutral ef-
fects on CV health.21 The hyperglycemia and its effect 
after acute myocardial infarction on cardiovascular 
outcomes in patients with type 2 diabetes mellitus 
(HEART2D) trial was designed to study the effects of 
either prandial (lispro) or basal (NPH twice daily or 
insulin glargine once daily) insulin on CV outcomes 
in 1,115 patients after myocardial infarction (MI). No 
differences in respect of CV events between prandial 
versus basal strategies were found.22 
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Insulin degludec is a novel basal insulin with a 
longer duration of action. In 2013, the FDA suspended 
approval of this insulin and requested additional CV 
outcomes data. The DEVOTE trial was designed to 
test its safety and efficiency in subjects with T2DM 
at high risk of CV events. Due to the satisfactory 
preliminary results, this trial has recently been ap-
proved by the FDA and is expected to be completed 
by September 2016.23
MeTfORMIN 
Metformin acts by reducing insulin resistance, par-
ticularly in the liver and skeletal muscle, suppressing 
hepatic gluconeogenesis and increasing insulin sensi-
tivity and peripheral glucose utilization.24 This drug 
has beneficial effects on lipid metabolism,24 causing a 
decrease in total cholesterol, Apo B concentrations and 
low-density lipoprotein (LDL) cholesterol (LDL-c)25 
and triglycerides (TG) and by increasing high-density 
lipoprotein (HDL) cholesterol (HDL-c).26 It has also 
been reported to cause a decrease in the proportion 
of small dense LDL particles.27 Metformin is also 
associated with weight loss.26 Metformin may have 
a moderate blood pressure (BP) lowering effect,28 
although the majority of studies have failed to identify 
any effect on BP.29 Metformin may be able to protect 
against diabetes-induced vascular disease,30 since it 
is able to decrease inflammation31 and preserve the 
endothelium,32 while it exhibits anti-thrombotic ef-
fects.33 On the other hand, metformin can cause folate 
malabsorption and vitamin B12 deficiency, which 
can lead to elevated homocysteine, an established 
risk factor for CVD.34 
CARDIOvAsCULAR sAfeTy Of MeTfORMIN: 
evIDeNCe fROM sTUDIes
The UK Prospective Diabetes Study (UKPDS) 
was a landmark study of the CV benefits of met-
formin, which demonstrated that, compared to the 
conventional-treatment group, metformin was able to 
reduce any diabetes-related endpoint, diabetes-related 
death and all-cause mortality. When compared to 
chlorpropamide, glibenclamide or insulin, metformin 
showed a more pronounced effect for any diabetes-
related endpoint, all-cause mortality and stroke.35 
Moreover, the metformin treated group displayed 
a sustained risk reduction for any diabetes-related 
endpoint, MI and death from any cause in the post-
trial follow-up.36 Metformin has been shown to lower 
all-cause mortality compared with other oral agents 
and insulin37 and to reduce composite CV endpoints 
compared with glipizide.38 It also appears to reduce the 
risk of macrovascular disease.39 Systematic reviews 
have revealed that treatment with metformin is as-
sociated with a decreased risk of CV mortality40 and 
with a significant reduction of CV events, especially 
in younger patients.41 However, in the A Diabetes 
Outcome Progression Trial (ADOPT) metformin 
did not demonstrate any advantage in terms of risk 
of death or CV events over glibenclamide or rosigli-
tazone.42 Moreover, the CV safety of metformin has 
been questioned since there is evidence of greater CV 
mortality when it is added to sulfonylurea.35 More 
specifically, a study found that patients treated with 
SU in combination with metformin were at higher 
risk of adverse CV outcomes than those treated with 
metformin alone.43 
A number of studies have pointed to beneficial 
effects of metformin in heart failure (HF), namely 
lower rates of mortality,44 mainly CV mortality,45 
and a lower risk of death and readmission for HF.46 
A recent systematic review has determined that met-
formin is at least as safe as other glucose-lowering 
treatments in patients with diabetes and HF, even in 
those with reduced left ventricular ejection fraction.47 
At present, metformin is recommended as first-line 
therapy in clinically stable patients with HF when 
their ventricular dysfunction is not severe.48 Among 
T2DM patients with documented coronary artery 
disease (CAD), metformin appears to be associated 
with lower mortality and CV risk than secretagogues.49
Several studies are in progress evaluating the po-
tential CV benefits of metformin. The METformin in 
DIastolic Dysfunction of MEtabolic syndrome (MET-
DIME) trial aims to evaluate if metformin added to the 
standard treatment of patients with metabolic syndrome 
(MS) is able to improve diastolic dysfunction.50 The 
Glycometabolic Intervention as an adjunct to Primary 
percutaneous intervention in ST elevation myocardial 
infarction (GIPS)-III trial aims to provide confirma-
tion that metformin is able to decrease infarct size, 
prevent adverse remodeling and ultimately improve 
systolic function.51 The Glucose Lowering In Non-
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diabetic hyperglycemia Trial (GLINT) was designed 
to establish the effectiveness and cost-effectiveness 
of metformin in preventing CV events in non-diabetic 
individuals with high glucose levels.52 
sULfONyLUReAs 
Sulfonylureas (SU) act by stimulating insulin re-
lease from pancreatic β-cells.53 SU also have a number 
of extra-pancreatic effects, although their clinical 
significance needs to be clarified.54 These drugs can 
reduce hepatic glucose production and hepatic insulin 
uptake and increase glucagon secretion by pancreatic 
α-cells.54,55 They increase insulin sensitivity in periph-
eral tissues55 as well as stimulate glucose utilization 
by these tissues.54,55 They may attenuate ischemically 
induced changes in cardiac electrical properties and 
prevent malignant arrhythmias.53 Gliclazide is able to 
reduce platelet adhesion, aggregation and hyperactiv-
ity and increase fibrinolysis.56 Gliclazide, in contrast 
to glyburide,53 is also thought to scavenge reactive 
oxygen species, thereby protecting pancreatic β-cells 
from apoptosis. Sulfonylurea treatment causes adverse 
effects, such as weight gain and hypoglycemia. The 
former usually ranges from 2 to 5 kg, whereas the latter 
is more likely to affect older individuals, those with 
impaired renal function or irregular meal schedules.57
In respect to CV risk safety, the main CV adverse 
effects of SU are weight gain and hypoglycemia, two 
important risk factors for CV adverse outcomes. The 
profiles of the different SU seem to slightly vary. 
In fact, hypoglycemia appears to be more frequent 
with glyburide,58 while glimepiride is associated 
with lower risk of hypoglycemia and less weight 
gain.59 According to a 2013 meta-analysis, SU can 
cause a slight reduction of HDL-c with no effects on 
BP and on the remaining lipid profile.60 However, a 
very recent meta-analysis revealed that SU have only 
a small effect on lipids, with a significant increase 
in both free fatty acids (FFA) and TG levels, and a 
decrease in LDL-c and HDL-c.61
CARDIOvAsCULAR sAfeTy Of sU: evIDeNCe 
fROM sTUDIes
No consistent evidence exists as to the association 
between SU use and risk of CVD in patients with 
T2DM. A meta-analysis revealed an increased risk of 
stroke and a significant increase in mortality, without 
affecting the overall incidence of major adverse cardiac 
events (MACE) with SU treatment.62 Another study 
has shown an increase in CV risk and mortality with 
all SU, except for gliclazide which was associated 
with a lower risk.63 In addition, in diabetic patients 
with documented CAD, glipizide and glyburide were 
associated with increased mortality,49 the latter probably 
because of its ability to impair ischemic precondition-
ing.64 SU have also been reported to reduce resting 
myocardial blood flow, to increase infarct size and to 
elicit proarrhythmic effects.65 Glimepiride however 
may be safer in patients with CVD, since it has no 
detrimental effects on ischemic preconditioning.59,64 SU 
seem to increase mortality when patients are submit-
ted to elective66 or emergency coronary angioplasty 
for acute MI.67 Globally, several retrospective stud-
ies have demonstrated that all-cause mortality68 and 
CV events and death69 are significantly increased in 
patients treated with SU compared with metformin. 
In the UKPDS, there was no increased mortality 
in the sulfonylurea-treated subjects;18 however, the 
addition of metformin to this group of patients was 
associated with an increased risk of diabetes-related 
death compared with sulfonylurea alone.70 A 2015 
study confirmed that treatment with a sulfonylurea 
plus metformin was associated with increased risks 
of CVD, MI and ischemic stroke.71 On the other hand, 
in the post-UKPDS, the sulfonylurea-insulin group 
exhibited a significant risk reduction of MI.19 Overall, 
large prospective randomized clinical trials72-74 did 
not report any increased CV mortality in patients 
treated with SU.
ThIAzOLIDINeDIONes
Thiazolidinediones (TZD) are ligands of the tran-
scription factor peroxisome proliferator-activated 
receptor γ (PPAR-γ) and act as insulin sensitizers.75 
Rosiglitazone was withdrawn from the European 
market by the EMA in September 2010 because of 
its CV risks;76 nonetheless, it continues to be used in 
the USA. In respect to pioglitazone, it is not recom-
mended as first-line therapy either by the EMA77 or 
by FDA.78
TZD have the potential to modulate several CV 
risk factors, including lipids, BP, inflammatory bio-
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markers, endothelial function and fibrinolytic status.79 
Both pioglitazone and rosiglitazone can cause an 
increase in HDL-c.75 LDL-c levels seem to remain 
unchanged with pioglitazone but to increase with 
rosiglitazone.75 Interestingly, both drugs seem able to 
increase LDL-c size particles.80 Pioglitazone decreases 
TG levels75 but has no effect on postprandial TG.81 
Although reports on the effect of rosiglitazone on 
TG are conflicting,75,80 it seems to be able to decrease 
their postprandial values.82 Rosiglitazone is also able 
to decrease FFA.82 TZD use is associated with weight 
gain,80 in subcutaneous rather than in visceral adipose 
tissue, and causes a reduction in liver fat.83 Data on 
the effect of TZD in BP have shown conflicting re-
sults, with some studies indicating improvements in 
BP control84 and others exhibiting no effect.85 Other 
studies have suggested potential anti-atherogenic 
effects for TZD.86 TZD adverse effects also include 
fluid retention and edema and, in fact, an increased 
risk of HF is the main CV concern with TZD use.87
CARDIOvAsCULAR sAfeTy Of TzD: 
evIDeNCe fROM sTUDIes
The Diabetes REduction Assessment with ramipril 
and rosiglitazone Medication (DREAM) trial found 
no increase in CV event rates with rosiglitazone, al-
though the rosiglitazone group developed significantly 
more HF events.88 The Rosiglitazone Evaluated for 
CV Outcomes in Oral Agent Combination Therapy 
for T2DM (RECORD) trial showed that rosiglitazone 
does not increase the risk of overall CV morbidity or 
mortality; nevertheless, it confirmed an increased risk 
of HF.89 In spite of this, issues related to trial design 
and data integrity led FDA to call for an independent 
reevaluation of the RECORD data, which reported 
similar results.90 A 2007 meta-analysis demonstrated 
that rosiglitazone was associated with a significant 
increase in the risk of MI and death from CV causes.91 
In 2010, the same authors repeated the meta-analysis 
and found an increased risk for MI, albeit less than 
before, and found no increased risk for CV mortality.92 
Other meta-analysis have suggested that rosiglitazone 
is associated with a significantly increased risk of MI 
and HF, without a significantly increased risk of CV 
mortality.93,94 The bypass angioplasty revasculariza-
tion investigation 2 diabetes (BARI 2D) trial in 2013 
reported that among patients with T2DM and CAD, 
rosiglitazone is not associated with an increase in 
major ischemic CV events.95
The PROspective pioglitAzone clinical trial in 
macroVascular events (PROactive) study has shown 
that in T2DM patients at high risk for macrovascu-
lar events, pioglitazone significantly reduced a pre-
specified secondary endpoint composed of death, 
non-fatal MI and stroke.96 It is important to note that 
in the pioglitazone group, there was an increased rate 
of any reported HF and HF leading to hospitalization, 
even though the rate of fatal HF was similar in both 
groups.96 In a subgroup analysis of the PROactive 
study, pioglitazone significantly decreased the risk of 
recurrent stroke97 and of fatal and nonfatal MI and acute 
coronary syndrome98 in high-risk patients with T2DM. 
Corroborating this, a meta-analysis has revealed that 
pioglitazone is associated with a significantly lower 
risk of death, MI or stroke in patients with T2DM.99 
HF is increased by pioglitazone, although there is 
no increase in the associated mortality.99 However, a 
recent study reported that pioglitazone treatment did 
not produce any significant reductions in the rate of 
primary CV events.100
Both pioglitazone and rosiglitazone seem to increase 
the risk of HF; nonetheless, the risk of CV death is 
not increased.101 Additionally, in a recent cochrane 
meta-analysis, PPAR-γ agonists were shown to reduce 
recurrent stroke and total events of CV death, as well 
as improving insulin sensitivity and carotid plaques 
stabilization.102
DIPePTIDyL PePTIDAse-4 INhIBITORs 
Five dipeptidyl peptidase-4 (DPP-4) inhibitors 
(DPP-4i), also named gliptins, are now available in 
Europe and worldwide (except vildagliptin in the 
USA): sitagliptin, saxagliptin, linagliptin, vildagliptin 
and alogliptin. Other DPP-4i are available only in 
Asia, namely anagliptin and teneligliptin, which are 
licensed in Japan, and gemigliptin in Korea. Other 
members of this class are in clinical development, 
including trelagliptin.103
Incretin hormones, such as glucagon-like pep-
tide-1 (GLP-1) and glucose-dependent insulinotropic 
peptide (GIP), are released from the gut in response 
to meals and are rapidly degraded by DPP-4. GLP-1 
stimulates insulin and suppresses glucagon secretion, 
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slows gastric emptying and enhances satiety leading 
to a decrease in food intake.104 The pharmacologic 
inhibition of DPP-4 allows extension of the biological 
effect of incretins. In addition to metabolic effects, 
DPP4 inhibition has been described as having other 
pleiotropic effects in the CV system related to several 
non-incretin substrates, like cytokines, chemokines 
and neuropeptides involved in inflammation, immu-
nity and vascular function.105 One of the best known 
substrates is stromal-derived factor-1a responsible for 
endothelial progenitor cells recruitment and vascular 
repair following ischemic injury.106 Potent vasodila-
tors, as for example substance P and bradykinin, are 
also degraded by DPP-4 and may improve fibrinolysis 
by stimulating tissue plasminogen activator (tPA).107 
Due to the multiple functions of these substances their 
ultimate role in disease prevention is still unclear.108
DPP-4i may have a beneficial role both in hyper-
tension and dyslipidemia, major risk factors for CVD. 
Human studies have indicated that DPP-4 inhibition 
allows endothelium-dependent relaxation mediated 
by nitric oxide, a molecule with important implica-
tions for BP.109 A meta-analysis pointed to a favorable 
effect of DPP-4i on cholesterol reduction, providing 
a small but significant reduction of CV risk.110 This 
class also has a low risk of causing hypoglycemia or 
weight gain.111 
CARDIOvAsCULAR sAfeTy Of DPP-4 
INhIBITORs: evIDeNCe fROM sTUDIes
Although not all of them, several studies on ex-
perimental animals have found that DPP-4 inhibi-
tion improves cardiac function. In animal models 
with diabetes and atherosclerosis, DPP-4 inhibition 
reduced atherosclerotic lesions and the expression 
of proinflammatory cytokines in these lesions,112 as 
well as monocyte activation and chemotaxis.113 In 
humans, patients not responding to metformin treated 
with sitagliptin or vildagliptin had a decrease in the 
intima media thickness of the carotid artery, a sur-
rogate marker for early atherosclerosis.114 
Some studies have suggested an increased risk of 
hospital admission for HF in patients on DPP-4i,115 
albeit the mechanism of action remains controver-
sial.116 There is no clear evidence of differences among 
drugs of this class. It is likely that the risk is greater in 
certain sub-populations of patients; however, current 
evidence is not yet sufficient to identify susceptible 
patients.117 
The Saxagliptin Assessment of Vascular Outcomes 
recorded in patients with diabetes mellitus-Thrombol-
ysis in Myocardial Infarction (SAVOR-TIMI) study 
evaluated 16,492 patients with T2DM, who had a 
history of, or were at risk for, CV events, that received 
saxagliptin or placebo. The study showed that the 
use of saxagliptin did not alter the rate of ischemic 
events; however, the rate of hospitalization for HF 
was increased.118 It is important to note that this was 
a secondary composite endpoint and further evalua-
tion is needed. The EXAmination of CV outcoMes 
with alogliptIN versus standard of carE (EXAMINE) 
study was a randomized, double-blind trial with 5,380 
patients with T2DM who had required hospitalization 
during the previous 15 to 90 days due to either acute 
MI or unstable angina. Alogliptin did not increase 
MACE, including MI, stroke or HF, compared to 
patients receiving placebo.119 The TECOS trial evaluat-
ing CV outcomes with sitagliptin was a randomized 
double-blinded trial involving 14,671 patients with 
T2DM and established CVD who added sitagliptin 
or placebo to their usual therapy. Recently published, 
this study showed that adding sitagliptin to therapy 
did not increase the risk of MACE, hospitalization for 
HF or other adverse events.120 Another recent study 
has suggested that, according to a pooled analysis of 
trials, linagliptin is not associated with increased CV 
risk versus active comparators or placebo in patients 
with T2DM.121 
Currently there are other ongoing randomized 
clinical trials comparing DPP-4i versus placebo added 
to conventional therapy in patients with T2DM. The 
CArdiovascular safety and renal microvascular out-
comE study with LINAgliptin in patients with T2DM 
(CARMELINA), lasting till 2018, has been designed to 
assess the long-term impact on CV morbidity, mortality 
and renal function of treatment with linagliptin.122 The 
CARdiovascular outcome trial of LINAgliptin versus 
glimepiride in patients with T2DM (CAROLINA) is 
a trial ongoing since 2010 comprising a comparison 
of a sulfonylurea with a DPP-4i. This trial is expected 
to provide considerable insight as it is unique in 
comparing head-to-head add-on therapy.123
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gLUCAgON-LIKe PePTIDe-1 ReCePTOR 
AgONIsTs
The actions of GLP-1 are mediated through the 
GLP-1 receptor (GLP-1R) that is expressed in pan-
creatic islet cells and in peripheral tissues.104 As a 
result of the wide distribution of GLP-1R, GLP-1 
seems to exert extra-pancreatic actions that can have 
beneficial effects on the CV, gastrointestinal and 
central nervous systems.124 Currently, the GLP-1R 
agonists (GLP-1 RA) approved for the treatment of 
T2DM are albuglutide, dulaglutide, exenatide and 
extended release exenatide, liraglutide and lixisena-
tide.125 Taspoglutide was stopped in phase III studies 
due to the unexpectedly high hypersensitivity reac-
tions reported.126 Semaglutide and efpeglenatide are 
currently in development and are, respectively, in 
phase III and II of clinical trials.127,128 
GLP-1 RA treatment seems to be associated with 
a favorable impact on several CV risk factors, namely 
BP, lipid profile and weight. In fact, several meta-
analyses have demonstrated that GLP-1 RA treat-
ment is associated with significant weight loss129-132 
and beneficial effects on lipid profile, decreasing 
LDL-c and TG.131,133 These drugs are able to reduce 
systolic BP (SBP), but not diastolic BP (DBP);132,134 
nonetheless, they also seem to be associated with 
a small increase in heart rate.132 Monotherapy with 
GLP-1 RA does not increase the risk of hypoglycemia 
in comparison with placebo, although is associated 
with higher frequencies of hypoglycemia when in 
combination with SU.129,130 It has also been reported 
that β-cell function was improved with GLP-1 RA 
(HOMA-B, proinsulin-to-insulin ratio).131
Several studies have supported a cardioprotective 
effect of native GLP-1 and GLP-1 RA on the vascular 
endothelium and myocardium, including vasodilation 
and anti-inflammatory effects.135-137 Evidence from 
clinical trials has shown that GLP-1 and GLP-1 RA 
can improve both left ventricular and endothelial 
functions and reduce arrhythmias in patients with 
or without diabetes and with coronary artery bypass 
graft, chronic HF and CAD.138-140
CARDIOvAsCULAR sAfeTy Of gLP-1: 
evIDeNCe fROM sTUDIes
Although pinpointing that drug or those drugs 
that will provide CV protection remains elusive, 
the available data confirm the CV safety of GLP-1 
RA. Ongoing randomized large-scale trials will be 
important to consolidate the results obtained so far. 
Indeed, several GLP-1 RA are undergoing long-term 
randomized trials to assess their CV safety – ELIXA 
(lixisenatide),141 LEADER (liraglutide),142 SUSTAIN 
6 (semaglutide),143 REWIND (dulaglutide),144 and 
EXSCEL (exenatide extended release).145 
At present, only the Evaluation of Lixisenatide in 
Acute Coronary Syndrome (ELIXA) study is com-
plete.141 Preliminary results were recently announced 
and have confirmed that the CV-safety profile of 
lixisenatide is non-inferior, although not superior, 
to placebo.146 Despite the limitations, meta-analyses 
performed to ascertain CV outcomes are also a source 
of evidence concerning CV safety. The results exclude, 
at least in the short term, any increase in CV morbidity 
and mortality in comparison with placebo or other 
active drugs.134,147,148 Besides, placebo-controlled trials 
have demonstrated that patients treated with GLP-1 




The sodium-glucose transporter-2 (SGLT-2) inhibi-
tors (SGLT-2i) are a new class of antidiabetic agents 
that inhibit glucose reabsorption from the kidney 
increasing urinary glucose excretion.149 The FDA and 
EMA have approved three inhibitors, canagliflozin, 
dapagliflozin and empagliflozin, with several oth-
ers being under late-stage clinical development.150 
Ipragliflozin, tofogliflozin and luseogliflozin have 
been approved for the treatment of T2DM in Japan.151 
Other compounds remain in development,152 as well 
as Lx4211, a dual sodium-glucose transporter 1 and 
2 inhibitor,153 and ISIS – 388626, an antisense oligo-
nucleotide (ASO) designed to block the expression 
of the SGLT2 gene in vivo.152 SGLT-2i protect the 
proximal tubular cells, most likely by blocking glu-
cose entry into the cell,54 and indirectly reduce insulin 
secretion, improve insulin sensitivity and increase the 
peripheral glucose uptake.155 This drug acts indepen-
dently of the severity of insulin resistance and β-cell 
failure;149 nonetheless, as the glomerular filtration 
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rate declines, its efficacy decreases.156 Recent reports 
have suggested that SGLT2i may increase the risk of 
developing diabetic ketoacidosis (DKA),157 although 
the pathophysiological mechanisms involved are not 
well defined. Selection of patients for this drug should 
therefore be carefully made.
In addition to lowering blood glucose, SGLT-2i 
may benefit such CV parameters as BP, weight and 
lipid profile.149,151 In many studies, SGLT-2i have 
shown a consistent reduction in SBP,158 with a less 
consistent reduction in DBP,159 and without a com-
pensatory increase in heart rate.149 These drugs also 
seem to improve endothelial function160 and to reduce 
arterial stiffness.161 SGLT2i promote glucose excretion 
in the urine, corresponding to a caloric loss of 200 to 
300 kilocalories per day and leading to weight loss.162 
SGLT-2i reduce total body weight, predominantly by 
reducing fat mass, visceral adipose tissue and subcu-
taneous adipose tissue.163 Plasma lipids are affected 
by SGLT-2i, which cause an increase in HDL-c and 
in LDL-c and a reduction in TG levels.149 To what 
extent these lipid changes translate into potential CV 
effects remains to be clarified, although they seem 
not to increase CV risk given the balanced effect of 
reduced hyperglycemia, BP and weight. Several studies 
have reported a reduction in urinary albumin excre-
tion164 and also in uric acid serum levels.162 Whether 
these effects contribute to a beneficial CV outcome 
is a question that will hopefully be answered through 
further studies.
This class of drugs has a low potential to induce 
hypoglycemia,158 unless used with SU or insulin.151 
SGLT-2i can also have a role in nephroprotection by 
preventing glomerular hyperfiltration;154 nevertheless, 
to what extent these effects may contribute to a renal 
or CV beneficial outcome is yet to be established.
CARDIOvAsCULAR sAfeTy Of sgLT-2I: 
evIDeNCe fROM sTUDIes
The recently published EMPA-REG OUTCOME 
study presented exciting CV results with empagliflo-
zin.165 In fact, empagliflozin was shown to signifi-
cantly reduce deaths among patients with T2DM and 
established CVD when compared with placebo. These 
patients exhibited a 14% reduction in the three-point 
MACE primary endpoint. This effect was mainly 
due to the benefits related to CV death, since em-
pagliflozin did not reduce the rate of nonfatal MI 
or nonfatal strokes. Overall, this drug displayed a 
38% reduction in CV death and a 32% reduction in 
all-cause mortality. A significant reduction in the key 
secondary endpoint, which was the primary composite 
endpoint plus hospitalization for unstable angina, 
was also apparent, as well as a 35% reduction in HF 
hospitalization. Interestingly, these effects occurred 
early in the trial.165 The diuretic effect is possibly the 
main factor responsible for these results, although in 
the long term the effect upon glycemia, BP and weight 
may also contribute to it. Recently, one study used 
the Archimedes Model to predict 20-year outcomes 
and found significant reductions in the risk of MI, 
stroke, CV death and all causes of death with SGLT-
2i treatment versus standard care.166 Nevertheless, 
to confirm these results, several trials are now in 
progress in order to evaluate the CV safety of the 
other SGLT-2i.150 The Multicenter Trial to Evaluate 
the Effect of Dapagliflozin on the Incidence of Car-
diovascular Events (DECLARE-TIMI58), expected 
to be finished in 2019, was designed to evaluate the 
effect of dapagliflozin on the incidence of CV events.167 
The Canagliflozin Cardiovascular Assessment Study 
(CANVAS), expected to complete data collection in 
2017, was also designed to evaluate the effects of cana-
gliflozin on MACE.168 The cardiovascular outcomes 
following treatment with ertugliflozin in participants 
with T2DM and established vascular disease trial was 
designed to assess the CV safety of ertugliflozin and 
it is expected to be completed in 2021.169
CONCLUsION AND CLINICAL IMPLICATIONs
This review analyzes the CV effects of antidia-
betic drugs while outlining the evidence available 
and enumerating the ongoing trials. Several drugs 
are now available to treat T2DM. Metformin, with 
solid evidence of having beneficial CV effects, is the 
first-line therapy for these patients. The direct heart 
benefits of metformin, under study in several trials, 
if confirmed, will reinforce the position of this drug 
as first-line therapy. Nonetheless, when metformin 
alone is not enough, other drugs are needed. Accord-
ing to the ADA/EASD algorithm, all drugs herein 
discussed are valid as second- and third-line therapy. 
The choice will also be based on the characteristics 
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of the patient. As diabetic patients are at high risk 
for CV morbidity and mortality, taking into account 
the CV safety of these drugs certainly constitutes 
knowledge of crucial importance to all clinicians 
dealing with this condition. 
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